Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Enbrel Shortage Strategies: Clinical Trials Will Provide “Bolus” Of Patients

Executive Summary

Immunex' ongoing Enbrel clinical trials will help provide a "bolus" of patients for the rheumatoid arthritis agent once the company expands its commercial capacity for the biologic

You may also be interested in...



Amgen files Enbrel plant sBLA

Amgen files sBLA Aug. 23 for Enbrel manufacturing facility in Rhode Island. Company expects to begin shipping from the plant immediately after approval, which is projected for first quarter 2003. Rhode Island plant will use same high-yield manufacturing process used at contract manufacturer Boehringer Ingelheim's facility (1"The Pink Sheet" April 29, p. 35). Etanercept shortage continues with 23,000 patients on waiting list as of July 24. Approximately 200,000 potential patients have signed up to receive information on rheumatoid arthritis through Amgen's "RA Access" unbranded TV ad campaign...

Amgen files Enbrel plant sBLA

Amgen files sBLA Aug. 23 for Enbrel manufacturing facility in Rhode Island. Company expects to begin shipping from the plant immediately after approval, which is projected for first quarter 2003. Rhode Island plant will use same high-yield manufacturing process used at contract manufacturer Boehringer Ingelheim's facility (1"The Pink Sheet" April 29, p. 35). Etanercept shortage continues with 23,000 patients on waiting list as of July 24. Approximately 200,000 potential patients have signed up to receive information on rheumatoid arthritis through Amgen's "RA Access" unbranded TV ad campaign...

Abbott D2E7 Monotherapy Use Should Afford Faster FDA Review, Abbott Says

Abbott is focusing on the need for a regular supply of an anti-TNF agent that can be dosed without methotrexate as a justification for requiring a faster review of D2E7 at FDA

Related Content

UsernamePublicRestriction

Register

PS039735

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel